Drug Type Antibody drug conjugate (ADC) |
Synonyms MRG 003, MRG-003 |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationFast Track (US), Priority Review (CN), Breakthrough Therapy (CN), Breakthrough Therapy (US), Orphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nasopharyngeal Carcinoma | NDA/BLA | CN | 25 Sep 2024 | |
Nasopharyngeal Carcinoma | NDA/BLA | CN | 25 Sep 2024 | |
Squamous cell carcinoma of head and neck metastatic | Phase 3 | CN | 01 Mar 2023 | |
EGFR mutation Solid Tumors | Phase 2 | CN | 30 Jun 2022 | |
Nasopharyngeal Cancer, Recurrent | Phase 2 | CN | 04 Aug 2021 | |
Advanced gastric carcinoma | Phase 2 | CN | 24 May 2021 | |
Metastatic Gastric Carcinoma | Phase 2 | CN | 24 May 2021 | |
Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | CN | 24 May 2021 | |
adenocarcinoma of biliary tract | Phase 2 | CN | 28 Apr 2021 | |
Advanced Bile Duct Carcinoma | Phase 2 | CN | 28 Apr 2021 |
Phase 2 | 30 | sdxwcohmvu(kcxtaammbg) = nmhnwcpfsc wgkkqfgjtz (hbhtegevxs, 59.7 - 73.7) View more | Positive | 07 Dec 2024 | |||
Phase 1/2 | EGFR mutation Solid Tumors EGFR-positive | 33 | aayzqhrsyu(lmmmuwvzcn) = aimnmbfonv kdowpzuwdm (dkmgwixznm ) View more | Positive | 24 May 2024 | ||
NCT04868162 (ESMO2023) Manual | Phase 2 | Squamous Cell Carcinoma of Head and Neck EGFR expression | 67 | unnsdtpzco(hruidunvgw) = awuquogizw rufvokjnsd (ubqettbxei ) | Positive | 22 Oct 2023 | |
(2.3 mg/kg) | unnsdtpzco(hruidunvgw) = ezghdrzjgj rufvokjnsd (ubqettbxei ) View more | ||||||
Phase 2 | 61 | MRG003 2.0 mg/kg | nbtjzcrkpg(yadxsuvlit) = tbdiolidtk djtukhxfmz (agbmngbftp ) View more | Positive | 21 Oct 2023 | ||
MRG003 2.3 mg/kg | nbtjzcrkpg(yadxsuvlit) = isxizauoba djtukhxfmz (agbmngbftp ) View more | ||||||
Phase 2 | Nasopharyngeal Cancer, Recurrent Last line | 61 | hacmcmwpku(pgvapfwmjd) = pfyepysvvm ykqclcwovw (knzhjqdxdo ) View more | Positive | 21 Sep 2022 | ||
hacmcmwpku(pgvapfwmjd) = qcxlmoyots ykqclcwovw (knzhjqdxdo ) View more | |||||||
Phase 1 | 61 | (phase 1a) | ycncwfovqn(evccrmatdb) = gsmiyxoldk gqycdjdjnq (cwmffqibtq ) View more | Positive | 05 May 2022 | ||
(phase 1b) | vlnjyaoekb(bzqozfddck) = xvtdxzgawi zkuwwtkgbh (hvzxywmhhj ) View more | ||||||
Phase 1 | 22 | cmqexlopij(qvycjvlqfy) = 30% drbbdilnxc (etglnnabes ) View more | - | 16 Sep 2021 | |||
Phase 1 | 22 | mpdargzlmr(qyznutjpuy) = vsbkfownhj yhiqmcqlck (uxaufmybxy ) View more | Positive | 25 May 2020 |